RxDoctor Payments Data

Deborah Reynolds

Adult Health · Eugene, ORNPI 1821162728

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Lilly USA, LLC at 30.8% of the total.

$879in general payments, 2019–2025

Across 35 payments — averaging $25.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$271
  • Exact Sciences$135
  • Amgen$120
  • E.r. Squibb & Sons, L.L.C.$40
  • AbbVie$40
  • Pfizer$39
  • plus $233 from 11 others

What the payments were for

  • Food & beverage$879100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$879 in reported general payments places this provider in the 70th percentile of 96 adult health providers in Oregon.

See all adult health providers in Oregon

Medicare billing

Part B allowed, 2024
$26,932
Medicare patients
44
Services billed
439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$59,986
JardianceEmpagliflozin36$32,729
TrulicityDulaglutide17$21,673
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$21,485
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl13$3,580
Ezetimibe98$3,097
Oxycodone Hcl114$2,493
Gabapentin64$2,148
Celecoxib40$2,129
Atorvastatin Calcium160$1,968
Lidocaine12$1,858
Levothyroxine Sodium130$1,319
Trazodone Hcl57$1,296
Potassium Chloride43$1,285
Pregabalin16$1,253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$39$59,98651 claims
Lilly USA, LLCTrulicity$271$21,67317 claims
GSKTrelegy Ellipta$31$21,48527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 96 adult health providers in Oregon.

Other adult health in Eugene

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →